Human Tissue (Authorisation) (Scotland) Bill: BRIA
Business and Regulatory Impact Assessment (BRIA) exploring the costs and benefits associated with the move to a soft opt out system of organ and tissue donation.
9. Summary
Summary costs and benefits table for the introduction of the soft opt-out system (Including theatre productivity):
| Soft opt out system | Total benefit yrs 1-5 :
|
Total cost yrs 1-5:
|
|---|---|---|
| 1 (Baseline) | £0.00 | £5.27 |
| 2 (Best estimate) | £48.62 | £13.74 |
| 3 (High estimate) | £102.46 | £22.54 |
The main costs surrounding the implementation of the soft opt-out system are derived from the need for awareness raising and education and from increases in resourcing costs for NHSBT and SNBTS. Future projections of costs were aggregated from years one to five to give a Present Cost* from £5.27m for the baseline, to £13.74m for the best estimate, up to £22.54m for the high estimate scenarios.
The positive health impact of receiving an organ can be measured in QALYs (Quality Adjusted Life Years). The monetary equivalent of these measured as Present Value* ranges from £0 for the baseline, to £45.33m for the best estimate, up to £95.51m for the high estimate scenarios. There might potentially be productivity improvements in theatre utilisation, (alythough there is no certainty around this which are estimated to range from £0m for the baseline, to £3.30m for the best estimate, up to £6.94m for the high estimate scenarios.
The Net Present Value ( NPV – the difference between Present Benefits and Present Costs) for the baseline (worst case scenario) is negative, as there are assumed increases in costs due to implementation, with no additional benefit from increased number of transplants. Both Best estimate and Higher estimate scenarios are net positive.
* Costs and Benefits discounted at 3.5% and 1.5% as per HMT guidance
Contact
There is a problem
Thanks for your feedback